Ariad Pharmaceuticals Inc fka ARIA

[glass_half_full]

It's an interesting question, that I don't know the answer to -- others may certainly recall whether there was a specific statement about this.

Since ponatinib was rationally designed to combat CML, a blood-related cancer, I think that blood-brain barrier permiability wasn't high on the list of requirements. But this would be an important factor for launching pell mell into a glioblastoma trial, I'd say -- regardless of how well LYN and LYNB are inhibited.

(Along the same lines, I have not heard the same type of discussion regarding brain mets in GIST as we do regarding ALK+ NSCLS with '113. I do know that certain cancers metastasize preferentially to certain areas.)